Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

LONDON, Nov. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).

Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.

This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivoi,ii via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

"We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW's first clinical study of cannabinoids as a potential treatment to inhibit tumor growth," stated Dr. Stephen Wri
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ...  The orders are for odour control projects in North ... Asia . "Bidding activity in 2015 ... and CEO. "After a high volume year for bidding in 2014, ... New Year.  The recent orders reflect the organization,s renewed focus on ...
(Date:3/3/2015)... 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and Chief Executive Officer of Neurocrine Biosciences, will ... Miami.   The live presentation takes place ... The presentation will be webcast and may be accessed ... Listeners are encouraged to visit the website ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies ... CFO, is joining its Board of Director as Chair ... officer at Zillow Group, Chad oversees all finance, treasury ... built the company,s core finance, treasury and accounting functions, ... and nine acquisitions. In 2013, he was named Puget ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Crown Bioscience, ... company, has launched a new Life Science division specializing ... preclinical research. , The first products released include ... controls, and soon to be released in vivo grade ... continue to expand their life science portfolio with additional ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2
... Nov. 13 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... of Savient Pharmaceuticals,will present a corporate update at the ... presentation is scheduled to begin on Tuesday, November 18, ... at the St. Regis Hotel in New,York City November ...
... Md., Nov. 13 PharmAthene, Inc.,(NYSE Alternext US: ... and chemical threats, today reported,financial and operational results ... 30, 2008., For the third quarter of ... $3.4 million in the same period of 2007. ...
... Biomaterial that Stops Bleeding Wins Professor Venture Fair at,U-Md. ... A University of,Maryland professor and doctoral student team who ... attention of a group of venture,capitalists and the title ... Nov. 12., Sponsored by the university,s Office of ...
Cached Biology Technology:Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 3Pharmathene Reports Third Quarter 2008 Financial and Operational Results 4Pharmathene Reports Third Quarter 2008 Financial and Operational Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 6Pharmathene Reports Third Quarter 2008 Financial and Operational Results 7Nano-Velcro Sticks With Venture Capitalists 2Nano-Velcro Sticks With Venture Capitalists 3
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has ... Market Overview" report to their offering. , ... that an individual is who she/he is claiming to be, ... a person,s unique physical characteristics, such as fingerprint, hand or ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... -- The Damon Runyon Cancer Research Foundation, a ... researchers and innovative cancer research, named 18 new ... Committee review. The recipients of this prestigious, ... and translational cancer research in the laboratories of ...
... discovered a dramatic increase of an easy-to-detect enzyme in the ... Hopkins scientists say the discovery could lead to a simple, ... before symptoms or complications occur and in time to reverse ... Diabetes , show the enzyme O-GlcNAcase is up to ...
... Researchers from Mount Sinai School of Medicine have identified a ... process by which information from a gene is used to ... which may help scientists gain insight into how muscle and ... of Nature . Using a combined approach of ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 5Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 6Hopkins team discovers sweet way to detect prediabetes 2Mount Sinai researchers discover new way diseases develop 2
... biologic production demands on cell and tissue ... cell populations. Therefore, both cell concentration and ... accurately and precisely. The new Vi-CELLTM Cell ... effective means to perform the trypan blue ...
... modification that plays an important role ... inflammation, cell-to-cell adhesion, and cell signaling. ... based Glycoprotein Isolation Kits, Concanavalin A ... that allow isolation of glycoproteins from ...
... SureLINK Bioconjugation Kit provides a powerful yet ... and nuceleic acids. The kit provides the ... reagents for quantifying conjugation efficiencies. It enables ... biotin and other tags with a variety ...
... The LS series of laser scanners is ... Expression Suite solution. ,Gene expression analysis, ... requirements essential to the advancement of ... rise to novel microarray formats and sizes. ...
Biology Products: